GlassScriptPhysician profile
Rajesh V Babu
NPI 1255352100
$4,625.46
in general payments reported to CMS, 2019-2025
29 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2022: $53.57 · 2023: $258 · 2024: $1,783 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,532 · Consulting Fee: $550 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.08 |
| Consulting Fee | $550.00 |
| Education | $162.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $724.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $477.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $401.35 | 2019-2025 | Fasenra, Tezspire, Daliresp |
| Bayer Healthcare Pharmaceuticals INC. | $400.00 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.34 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $291.56 | 2024-2025 | Dupixent |
| Genzyme Corporation | $258.90 | 2024-2025 | |
| Abbvie INC. | $244.44 | 2024-2025 | |
| Inspire Medical Systems, INC. | $213.03 | 2024-2025 | Inspire |
| Verona Pharma, INC. | $174.81 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $172.31 | 2024-2025 | Nuzyra |
| Abbott Laboratories | $148.07 | 2024 | Jot Dx |
| Insmed, INC. | $141.82 | 2022-2025 | Arikayce |
| United Therapeutics Corporation | $130.67 | 2024-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $93.63 | 2019-2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $52.70 | 2025 | Cabenuva |
| Actelion Pharmaceuticals US, INC. | $49.73 | 2024 | Uptravi |
| Philips North America LLC | $42.61 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Janssen Pharmaceuticals, INC | $41.55 | 2024 | Xarelto |
| Avadel Cns Pharmaceuticals, LLC | $34.54 | 2025 | Lumryz |
| Electromed, INC. | $33.44 | 2024 | Smartvest |
| Grifols USA, LLC | $27.94 | 2019 | |
| Harmony Biosciences LLC | $21.45 | 2024 | |
| Lilly USA, LLC | $17.86 | 2025 | Zepbound |
| Viatris Specialty LLC | $16.29 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $15.84 | 2025 | Glassia |
| Otsuka America Pharmaceutical, INC. | $14.81 | 2019 | |
| Baxter Healthcare | $12.75 | 2022 | |
| Zoll Medical Corporation | $10.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Babu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.